Merck’s $6.7B acquisition of Terns Pharmaceuticals highlights huge potential in CML therapies. Why analysts see Enliven’s ELVN-001 as a best-in-class winner with strong takeover appeal.
Merck is buying Terns Pharmaceuticals for $6.7 billion to add TERN-701, a promising new oral drug for chronic myeloid leukemia (CML). The move strengthens its cancer pipeline as Keytruda patent expiry nears in 2028.
Novo Nordisk CEO says company is open to acquisitions of any size to strengthen its obesity drug portfolio following competition from Eli Lilly and loss of Metsera to Pfizer.
Terns Pharmaceuticals (TERN) announces encouraging Phase 1 results for TERN-701, showing 64% response rates in relapsed/refractory chronic myeloid leukemia patients with favorable safety profile.
William Blair upgraded Terns Pharmaceuticals (TERN) to Outperform following impressive Phase 1 CARDINAL trial results of TERN-701 in chronic myeloid leukemia, showing a 75% overall major molecular response rate and strong safety profile.
Terns Pharmaceuticals halts development of oral GLP-1 obesity treatment TERN-601 after Phase 2 trial shows modest weight loss and liver safety concerns.
